Pharma major, Biocon Pharma, has received final approvals from the U.S. Food and Drug Administration (FDA) for its ...

The company announced that it has secured three orders valued at around ₹500 crore from Power Grid Corporation of India Ltd ...

The rise in Biocon share price came after the company announced that its wholly-owned subsidiary, Biocon Pharma, has received ...

The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

If you’re interested in biotechnology stocks, billionaires Julian and Felix Baker are the ones to turn to.  According to ...

The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after ...

Biocon rose 1.08% to Rs 318.20 after the company said that Biocon Pharmahas received final approvals from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug applications (ANDAs) ...

(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...

The ELM-2 trial included 5 independent disease-specific groups (DLBCL, FL, mantle cell lymphoma, marginal zone lymphoma and other subtypes of B-cell non-Hodgkin lymphoma). Among the 128 R/R FL ...

Guggenheim analyst Michael Schmidt raised the firm’s price target on BeiGene (ONC) to $348 from $345 and keeps a Buy rating on the shares after ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.